Filing Details
- Accession Number:
- 0001790340-24-000034
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-21 09:06:10
- Reporting Period:
- 2024-03-15
- Accepted Time:
- 2024-03-21 09:06:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1790340 | Immuneering Corp | IMRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1870437 | Matthew Brett Hall | 245 Main Street Second Floor Cambridge MA 02142 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2024-03-15 | 6,211 | $1.62 | 338,896 | No | 4 | A | Direct | |
Class A Common Stock | Acquisiton | 2024-03-20 | 7,000 | $2.86 | 345,896 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | P | Direct |
Footnotes
- The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
- The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024.
- In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024.